Work

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR

Year: 2017

Type: article

Abstract: // Shencun Fang 1, 3, * , Meiling Zhang 2, * , Guihong Wei 3 and Kai-Hua Lu 2 1 Department of Respiratory Medicine Center, Nanjing Chest Hospital, Nanjing, Jiangsu, China 2 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China 3 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China * These authors contributed equally to this work Correspondence to: Kai-Hua Lu, email: [email protected] Keywords: non-small-cell lung cancer; angiogenesis; apatinib; VEGFR-2 Received: August 24, 2017 Accepted: November 14, 2017 Published: December 22, 2017 ABSTRACT Objectives: This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. Materials and Methods: We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and adverse events (AEs) were reveiwed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors. Results: 36 patients were evaluable for safety and efficacy. 6 patients obtained partial response, and 21 showed stable disease. The ORR and DCR were 16.7% and 75%, respectively. The median PFS and OS were 4.5 months and 8.2 months, respectively. Prognostic variable for a longer OS was good performance status ( p = 0.015). Most adverse reactions were mild or moderate. Conclusions: Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity.

Source: Oncotarget

DOI: 10.18632/oncotarget.23612

Authors: Shencun Fang, Meiling Zhang, Guihong Wei, Kai-Hua Lu

Institutions: Nanjing Chest Hospital, Jiangsu Province Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: National Natural Science Foundation of China